Interactive modules by Olga Goodman, MD.Copyright protected · Read termsClose terms

All RheumaView™ interactive modules, quizzes and educational cases are original works developed by Olga Goodman, MD.

Without the author’s prior written permission, you may not copy or republish these modules or their components; extract, reuse or modify their original software code (“engines”); or use that code to build your own modules, quizzes or other products.

You may not claim these works as your own or remove or replace the author’s name or copyright notices. When quoting material, credit Olga Goodman, MD, identify the source and include a direct link to the original.

Free or public access is provided for learning and does not grant permission to copy, adapt or redistribute the materials. Unauthorized use of protected material may constitute copyright infringement. Exceptions and limitations provided by applicable law remain unaffected.

Sharing direct links to the modules is welcome.

© 2026 Olga Goodman, MD. All rights reserved.

Professional Essentials · Free · No registration

Vasculitis

Recognizing organ threats, confirming the vascular process and choosing phenotype-specific treatment.

Clinically reviewed: October 4, 2026 · Avacopan update: November 11, 2026 · Free to read · English

Vasculitis means inflammation of blood-vessel walls, but the clinical task is more specific: identify the affected vascular territory, determine what function is threatened and establish why the injury is occurring. Vessel size organizes the differential; it is not a diagnosis. Primary vasculitis, infection, drug-associated injury, immune-complex disease, thrombosis and noninflammatory vasculopathy can produce overlapping findings. Treatment intensity follows the current organ threat and mechanism, not the number of positive tests.

1. Identify the consequence that cannot wait

New visual disturbance with suspected giant cell arteritis, rapidly deteriorating kidney function, hypoxemic pulmonary hemorrhage, new motor neuropathy, bowel ischemia or a threatened limb requires urgent assessment. Hemoptysis may be absent in alveolar hemorrhage, and glomerulonephritis may be painless. A modest inflammatory-marker result does not neutralize a dangerous clinical syndrome.

Stabilization, infection assessment and diagnostic confirmation often proceed together. Obtain decisive blood, urine, imaging and tissue evidence promptly when feasible, but do not delay time-critical treatment merely to complete a checklist. In suspected GCA with visual ischemia, arrange urgent ophthalmic and medical care while confirmation is organized.

Record baseline function and tempo explicitly: rising creatinine over days, a new oxygen requirement, progressive foot drop or transient monocular visual loss conveys more than a nonspecific label of active disease. In established vasculitis, a new problem may represent relapse, damage, infection, treatment toxicity or several processes at once.

Clinical reasoning — full chapter →
GPA / MPA: organ threat →
GCA: threatened vision → Professional access required

2. Make confirmation answer a defined question

Clinical assessment should connect skin, ENT, pulmonary, renal, neurological, eye and vascular findings in time. Review medications, infections, exposures, previous immunosuppression and relevant malignancy history. Examine pulses and blood pressure appropriately when large-vessel disease is plausible. An arm pressure downstream from stenosis may underestimate systemic pressure.

Use antigen-specific PR3-ANCA and MPO-ANCA in a compatible setting. Positive ANCA can occur with infections or drug-associated disease; negative ANCA does not exclude vasculitis. Pair creatinine with urine microscopy and protein quantification. Select complement, cryoglobulins, hepatitis testing and anti-GBM antibodies according to the syndrome, not as an indiscriminate panel.

Biopsy and imaging supply complementary evidence. Choose involved tissue with useful yield and acceptable risk; a negative sample may reflect location, timing or treatment. For suspected large-vessel disease, imaging must address wall inflammation, lumen and structural complications. Classification criteria organize research populations after appropriate clinical selection and are not screening rules for unexplained symptoms.

Diagnostic confirmation: tests, imaging and biopsy →
GPA / MPA: diagnostic mimics → Professional access required

3. Separate AAV induction from maintenance

GPA and MPA are clinical phenotypes within the ANCA-associated spectrum; PR3 and MPO are informative associations, not interchangeable disease names. For organ-threatening disease, EULAR and KDIGO support rituximab- or cyclophosphamide-based induction with glucocorticoids. Choose with relapse history, renal severity, fertility, infection risk and previous exposure in mind. Use a deliberate glucocorticoid-reduction plan.

Plasma exchange is not routine treatment for every AAV presentation. KDIGO supports consideration in selected severe renal disease or hypoxemic alveolar hemorrhage, and addition in anti-GBM overlap. The anticipated benefit, infection risk and competing diagnoses require multidisciplinary judgment. Persistent urinary abnormalities after treatment do not automatically establish active renal vasculitis.

Maintenance commonly uses rituximab or azathioprine in appropriate patients. Duration and surveillance reflect relapse risk, organ consequences and toxicity. Do not escalate solely for an ANCA rise without clinical assessment.

Avacopan — targeted update, 11 November 2026. FDA/CDER proposed withdrawal of Tavneos approval on 27 April 2026; the FDA page continues to describe a proposal, not a completed US withdrawal. The May 2026 US label strengthened liver-safety precautions. NEJM retracted ADVOCATE on 29 June 2026 because of undisclosed post-lock, unblinded reassessment of primary-endpoint data. The European Commission revoked EU authorisation on 4 August 2026; EMA advises no new starts and transition of existing patients to alternatives. The MHRA announced separate UK restrictions on 1 September. Older efficacy statements and guidelines must be read against these events. Patients taking avacopan need prompt review with the prescribing team and a jurisdiction-specific transition and liver-monitoring plan.

GPA / MPA: induction, maintenance and recurrent activity → Professional access required

4. Treat large-vessel inflammation and assess its damage

Suspect GCA in the appropriate older adult with new cranial, visual, polymyalgic or large-vessel symptoms; headache is not obligatory. EULAR imaging guidance recommends ultrasound, including axillary arteries, as first-line imaging where suitable expertise exists. Biopsy and other imaging remain useful according to probability, availability and the vascular question. A negative test must be interpreted in context.

Glucocorticoids provide rapid initial control; steroid-sparing choices require individualized assessment. Tocilizumab is established, and upadacitinib has a US adult GCA indication with important infection, thrombosis, cardiovascular and malignancy precautions. The 2025 EULAR recommendations, published in 2026, recommend rapid specialist assessment, within 24 hours for suspected GCA, and immediate glucocorticoids when suspicion is strong while confirmation proceeds.

In Takayasu arteritis, assess the aorta and branches, perfusion and blood-pressure measurement reliability. Active inflammation, fixed stenosis and aneurysmal complications need separate judgments. Persistent structural narrowing is not by itself proof that immunosuppression failed. Coordinate revascularization decisions with vascular specialists; disease control does not remove the need to monitor structural complications.

Giant cell arteritis — full chapter →
Takayasu arteritis — full chapter → Professional access required

5. Preserve the distinct pathways of other vasculitides

In EGPA, assess asthma/ENT disease, eosinophilic tissue injury and vasculitic organ damage separately, especially the heart and nerves. Negative ANCA or treatment-suppressed eosinophils does not exclude dangerous disease. Eosinophil-directed therapies have evidence in selected relapsing/refractory EGPA, including MANDARA; this does not establish them as substitutes for acute organ-rescue therapy.

PAN involves muscular arteries; glomerulonephritis or pulmonary capillaritis should reopen the diagnosis. Check relevant hepatitis B and consider DADA2 in a suggestive phenotype. Cryoglobulinemic disease requires identification of infection, autoimmune disease or a clone, alongside organ-directed treatment; sample handling can affect cryoglobulin detection.

In IgA vasculitis, assess urine, blood pressure and kidney function even when the rash improves; glucocorticoids solely to prevent nephritis are not recommended. Behçet disease requires organ-specific care, with aneurysm and bleeding assessment informing anticoagulation decisions. Kawasaki and single-organ vasculitis likewise require their own pathways.

EGPA — full chapter →
Polyarteritis nodosa — full chapter →
Cryoglobulinemic vasculitis — full chapter →
IgA vasculitis — full chapter →
Behçet disease — full chapter →
Kawasaki disease — full chapter →
Skin-limited vasculitis — full chapter →
Primary CNS vasculitis — full chapter →
Nonsystemic vasculitic neuropathy — full chapter →
Isolated aortitis — full chapter → Professional access required

6. Measure remission, damage and treatment burden separately

Before immunosuppression, plan relevant infection screening, vaccination, Pneumocystis prevention, bone protection and fertility or pregnancy counseling. Rituximab requires attention to hepatitis B reactivation and immunoglobulin depletion; cyclophosphamide adds cumulative marrow, bladder and reproductive risks. Laboratory surveillance must match the drug and organ function.

Interpret follow-up tests against the treatment context. IL-6 blockade can suppress CRP, so a normal result cannot independently rule out relapse or serious infection. Conversely, persistent fatigue, pain or an isolated laboratory abnormality should prompt assessment before further immunosuppression. When clinical activity and previous vascular damage are difficult to separate, targeted imaging or tissue review may be more useful than empiric dose escalation. Document the working explanation and the finding that would change it; this makes reassessment safer when several specialties share care.

Follow the outcome that treatment was intended to protect: filtration, oxygenation, motor function, vision or perfusion. Review infections, adverse effects, adherence and functional recovery alongside disease activity. A patient may need rehabilitation despite controlled inflammation. Give clear instructions for urgent symptoms, a dated monitoring plan and ownership of abnormal results across specialties.

Selected sources

Evidence is linked where it changes clinical decisions. Detailed chapters retain their individual access requirements.

Share this page

FacebookLinkedInXWhatsAppTelegram

Topics: Vasculitis